What SEC filings does Kura Oncology, Inc. submit to the SEC?

Kura Oncology, Inc. (KURA) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about KURA?

A Form 4 for KURA discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Kura Oncology, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for KURA?

The 10-K is Kura Oncology, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all KURA SEC filings directly on EDGAR?

You can view all historical Kura Oncology, Inc. filings on the SEC EDGAR company page for KURA. Each filing card on this page links directly to the original SEC document.

How often does Kura Oncology, Inc. file with the SEC?

Kura Oncology, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling KURA shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

KURA SEC Filing News — Kura Oncology, Inc.

Latest SEC filings for Kura Oncology, Inc. (KURA) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-29.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabe…

Sector: Healthcare Industry: Biotechnology Market Cap: $819.8M CIK: 1422143

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for KURA currently lean bearish. Of the 20 filing records displayed, 6 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 1 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

KURA Filing Activity Snapshot 2026-08-24 — 2026-09-29

Insider Transactions (Form 4)

1 buy vs 6 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.24M

WILSON TROY EDWARD (Director, President and CEO) · 2026-08-24

100,000 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for Kura Oncology, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 6 open-market sale, 1 compensation award and 1 open-market purchase. 7 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×6: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×1: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Open-market sale Insider Selling 2026-09-29

KURA insider Bair Teresa Brophy (Chief Legal Officer) sold 8,442 shares (~$88.6K)

Bair Teresa Brophy, listed as Chief Legal Officer at Kura Oncology, Inc., reported an open-market sale of 8,442 KURA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	8,442	$10.50	$88.6K

Filing: Form 4 (Insider Transaction) Insider: Bair Teresa Brophy (Chief Legal Officer) Shares: 8,442 Est. Value: $88.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-29

KURA insider FORD KATHLEEN (Chief Operating Officer) sold 10,574 shares (~$111.9K)

FORD KATHLEEN, listed as Chief Operating Officer at Kura Oncology, Inc., reported an open-market sale of 10,574 KURA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	6,906	$10.50	$72.5K
`S`	Open-market sale	3,668	$10.75	$39.4K

Filing: Form 4 (Insider Transaction) Insider: FORD KATHLEEN (Chief Operating Officer) Shares: 10,574 Est. Value: $111.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-29

KURA insider Leoni Mollie (Chief Medical Officer) sold 41,250 shares (~$440.2K)

Leoni Mollie, listed as Chief Medical Officer at Kura Oncology, Inc., reported an open-market sale of 41,250 KURA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	12,448	$10.50	$130.7K
`S`	Open-market sale	28,802	$10.75	$309.6K

Filing: Form 4 (Insider Transaction) Insider: Leoni Mollie (Chief Medical Officer) Shares: 41,250 Est. Value: $440.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-29

KURA insider DOYLE THOMAS JAMES (SVP, Finance & Accounting) sold 4,607 shares (~$48.4K)

DOYLE THOMAS JAMES, listed as SVP, Finance & Accounting at Kura Oncology, Inc., reported an open-market sale of 4,607 KURA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	4,607	$10.50	$48.4K

Filing: Form 4 (Insider Transaction) Insider: DOYLE THOMAS JAMES (SVP, Finance & Accounting) Shares: 4,607 Est. Value: $48.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-29

KURA insider Powl Brian T. (Chief Commercial Officer) sold 32,450 shares (~$345.0K)

Powl Brian T., listed as Chief Commercial Officer at Kura Oncology, Inc., reported an open-market sale of 32,450 KURA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	9,020	$10.50	$94.7K
`S`	Open-market sale	8,000	$10.56	$84.5K
`S`	Open-market sale	15,430	$10.75	$165.9K

Filing: Form 4 (Insider Transaction) Insider: Powl Brian T. (Chief Commercial Officer) Shares: 32,450 Est. Value: $345.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-25

KURA insider Burrows Francis (Chief Scientific Officer) sold 20,726 shares (~$224.5K)

Burrows Francis, listed as Chief Scientific Officer at Kura Oncology, Inc., reported an open-market sale of 20,726 KURA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	30,000	$6.15	$184.5K
`S`	Open-market sale	20,726	$10.83	$224.5K
`M`	Option exercise derivative · Stock Option (Right to Buy)	30,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Burrows Francis (Chief Scientific Officer) Shares: 20,726 Est. Value: $224.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-10

KURA insider Form 4 filed for equity award, exercise, or tax withholding

Fulk Jennifer (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Option to purchase common stock	450,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Fulk Jennifer (Chief Financial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-24

KURA insider WILSON TROY EDWARD (Director, President and CEO) bought 100,000 shares (~$1.24M)

WILSON TROY EDWARD, listed as Director, President and CEO at Kura Oncology, Inc., reported an open-market purchase of 100,000 KURA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	100,000	$12.39	$1.24M

Filing: Form 4 (Insider Transaction) Insider: WILSON TROY EDWARD (Director, President and CEO) Shares: 100,000 Est. Value: $1.24M

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 10 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Kura Oncology, Inc. has 10 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-29

KURA Form 144 filed for proposed insider sale by BRIAN POWL (15,430 shares) ~$163.7K

BRIAN POWL filed a Form 144 with the SEC indicating intent to sell KURA (Kura Oncology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: BRIAN POWL Shares: 15,430 Est. Value: $163.7K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-29

KURA Form 144 filed for proposed insider sale by MOLLIE LEONI (28,802 shares) ~$305.6K

MOLLIE LEONI filed a Form 144 with the SEC indicating intent to sell KURA (Kura Oncology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: MOLLIE LEONI Shares: 28,802 Est. Value: $305.6K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-29

KURA Form 144 filed for proposed insider sale by KATHLEEN FORD (3,668 shares) ~$38.9K

KATHLEEN FORD filed a Form 144 with the SEC indicating intent to sell KURA (Kura Oncology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KATHLEEN FORD Shares: 3,668 Est. Value: $38.9K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-28

KURA Form 144 filed for proposed insider sale by POWL BRIAN T (9,020 shares) ~$97.1K

POWL BRIAN T filed a Form 144 with the SEC indicating intent to sell KURA (Kura Oncology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: POWL BRIAN T Shares: 9,020 Est. Value: $97.1K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-28

KURA Form 144 filed for proposed insider sale by FORD KATHLEEN (6,906 shares) ~$74.3K

FORD KATHLEEN filed a Form 144 with the SEC indicating intent to sell KURA (Kura Oncology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: FORD KATHLEEN Shares: 6,906 Est. Value: $74.3K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-28

KURA Form 144 filed for proposed insider sale by BAIR TERESA BROPHY (8,442 shares) ~$90.8K

BAIR TERESA BROPHY filed a Form 144 with the SEC indicating intent to sell KURA (Kura Oncology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: BAIR TERESA BROPHY Shares: 8,442 Est. Value: $90.8K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-28

KURA Form 144 filed for proposed insider sale by LEONI MOLLIE (12,448 shares) ~$133.9K

LEONI MOLLIE filed a Form 144 with the SEC indicating intent to sell KURA (Kura Oncology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: LEONI MOLLIE Shares: 12,448 Est. Value: $133.9K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-28

KURA Form 144 filed for proposed insider sale by DOYLE THOMAS JAMES (4,607 shares) ~$49.6K

DOYLE THOMAS JAMES filed a Form 144 with the SEC indicating intent to sell KURA (Kura Oncology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: DOYLE THOMAS JAMES Shares: 4,607 Est. Value: $49.6K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-28

KURA Form 144 filed for proposed insider sale by BRIAN POWL (8,000 shares) ~$86.1K

Filing: Form 144 (Proposed Sale Notice) Insider: BRIAN POWL Shares: 8,000 Est. Value: $86.1K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-24

KURA Form 144 filed for proposed insider sale by FRANCIS J BURROWS (20,726 shares) ~$224.5K

FRANCIS J BURROWS filed a Form 144 with the SEC indicating intent to sell KURA (Kura Oncology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: FRANCIS J BURROWS Shares: 20,726 Est. Value: $224.5K

View on SEC EDGAR → Open Filing Document →

Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Kura Oncology, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-09

KURA filed 8-K — material company event

Kura Oncology, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-09-08

KURA filed 8-K — material company event

Kura Oncology, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

How we classify Kura Oncology, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on KURA. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — KURA SEC Filings

More Tools for KURA

KURA Full Stock Analysis KURA Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper KURA analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the KURA stock analysis page.

KURA Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer